Blinatumomab Plus Low-Dose DLI in High-Risk B-ALL Post-Transplantation
A prospective study is set to evaluate the safety and efficacy of blinatumomab combined with low-dose DLI in high-risk B-ALL patients after transplantation.
Indication
Clinical and regulatory intelligence for B-cell Acute Lymphoblastic Leukemia (B-ALL) with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.